HEMO
NEUTRALHemogenyx Pharmaceuticals Announces Director Shareholding Changes
The biotechnology company has announced changes to a director's shareholding position.
Hemogenyx Pharmaceuticals
688.00GBX
9.73%
Market Cap
41.56M
Volume
15.34k
38% of avg
P/E Ratio
NaN
EPS (TTM)
Beta
1.33
Day Range
598.00p - 688.00p
52 Week Range
124.00p688.00p1,800.00p
688.00p
Upcoming Events
Mid Q2 2026
Anticipated update on Estonian hospital exemption pathway commercialization
June 2026
Completion of process development for customized ultrafast manufacturing of Hemogenyx's CAR-T therapy
High Impact Event
HEMO
NEUTRALHemogenyx Pharmaceuticals Provides Update on Share Admission
The biopharmaceutical group provides an update on the admission of new ordinary shares, with the FCA scheduling the admission hearing for early January 2026.
HEMO
BADHemogenyx Pharmaceuticals Raises £190,000 Through Warrant Exercises
The biotechnology company has raised £190,000 through the exercise of warrants, but the new shares were issued at a 72.9% discount to the previous closing price, a concerning sign for investors.
HEMO
NEUTRALHemogenyx Pharmaceuticals Announces Director Dealings
The biotechnology company has announced changes to its major shareholders.
HEMO
NEUTRALHemogenyx Pharmaceuticals Provides Clinical Trial Update
The biotechnology company provides an update on its ongoing Phase I clinical trial for its HG-CT-1 therapy, including DSMB clearance to advance to the next dose level and the initiation of pediatric patient recruitment.
HEMO
NEUTRALHemogenyx Pharmaceuticals Receives Clearance for Pediatric Enrolment in HG-CT-1 Trial
The biotechnology company has received clearance to enroll children and adolescents in its ongoing HG-CT-1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia.
HEMO
BADHemogenyx Pharmaceuticals Reports Clinical Progress Amid Financial Challenges
The biopharmaceutical firm reports promising clinical progress in its Phase I trial for AML treatment. However, financial challenges loom with doubled losses and urgent funding needs.
HEMO
GOODHemogenyx Pharmaceuticals Signs Letter of Intent to Advance HG-CT-1 CAR-T Therapy in Estonia
The biotechnology company has signed a letter of intent with a leading Estonian cell therapy firm to advance the commercialization of its HG-CT-1 CAR-T therapy for relapsed or refractory acute myeloid leukemia.
HEMO
NEUTRALHemogenyx Pharmaceuticals Announces Holding(s) in Company
The healthcare company has announced changes to its major shareholders.
HEMO
NEUTRALHemogenyx Pharmaceuticals Provides Update on HG-CT-1 CAR-T Therapy Trial
The biotechnology company reports successful treatment of a third patient in the ongoing clinical trial of its HG-CT-1 CAR-T therapy for relapsed/refractory acute myeloid leukemia.